vs
Side-by-side financial comparison of AVANOS MEDICAL, INC. (AVNS) and JFrog Ltd (FROG). Click either name above to swap in a different company.
AVANOS MEDICAL, INC. is the larger business by last-quarter revenue ($180.9M vs $145.3M, roughly 1.2× JFrog Ltd). AVANOS MEDICAL, INC. runs the higher net margin — -0.7% vs -10.5%, a 9.7% gap on every dollar of revenue. On growth, JFrog Ltd posted the faster year-over-year revenue change (25.2% vs 0.7%). JFrog Ltd produced more free cash flow last quarter ($49.9M vs $21.3M). Over the past eight quarters, JFrog Ltd's revenue compounded faster (20.4% CAGR vs 4.4%).
Avanos Medical, Inc. is a medical technology company making clinical medical devices. The company consists of two franchises – Pain Management and Chronic Care – that address reducing the use of opioids while helping patients recover faster and preventing infection.
JFrog Ltd is a global DevOps technology provider that delivers end-to-end software release, artifact management, and security solutions. It serves clients across tech, finance, retail, and manufacturing sectors, helping teams streamline development and delivery workflows for cloud, on-premises, and hybrid infrastructure.
AVNS vs FROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $180.9M | $145.3M |
| Net Profit | $-1.3M | $-15.2M |
| Gross Margin | 47.5% | 77.9% |
| Operating Margin | 1.4% | -14.7% |
| Net Margin | -0.7% | -10.5% |
| Revenue YoY | 0.7% | 25.2% |
| Net Profit YoY | 99.7% | 34.4% |
| EPS (diluted) | $-0.02 | $-0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $180.9M | $145.3M | ||
| Q3 25 | $177.8M | $136.9M | ||
| Q2 25 | $175.0M | $127.2M | ||
| Q1 25 | $167.5M | $122.4M | ||
| Q4 24 | $179.6M | $116.1M | ||
| Q3 24 | $170.4M | $109.1M | ||
| Q2 24 | $171.7M | $103.0M | ||
| Q1 24 | $166.1M | $100.3M |
| Q4 25 | $-1.3M | $-15.2M | ||
| Q3 25 | $-1.4M | $-16.4M | ||
| Q2 25 | $-76.8M | $-21.7M | ||
| Q1 25 | $6.6M | $-18.5M | ||
| Q4 24 | $-397.3M | $-23.2M | ||
| Q3 24 | $4.3M | $-22.9M | ||
| Q2 24 | $1.8M | $-14.3M | ||
| Q1 24 | $-900.0K | $-8.8M |
| Q4 25 | 47.5% | 77.9% | ||
| Q3 25 | 48.4% | 77.4% | ||
| Q2 25 | 52.6% | 76.3% | ||
| Q1 25 | 53.6% | 75.3% | ||
| Q4 24 | 54.6% | 75.4% | ||
| Q3 24 | 54.5% | 75.0% | ||
| Q2 24 | 55.7% | 78.8% | ||
| Q1 24 | 57.1% | 79.5% |
| Q4 25 | 1.4% | -14.7% | ||
| Q3 25 | 0.1% | -15.8% | ||
| Q2 25 | -42.6% | -20.4% | ||
| Q1 25 | 6.1% | -18.8% | ||
| Q4 24 | -233.0% | -21.9% | ||
| Q3 24 | 7.0% | -27.4% | ||
| Q2 24 | 3.7% | -18.6% | ||
| Q1 24 | 2.4% | -16.6% |
| Q4 25 | -0.7% | -10.5% | ||
| Q3 25 | -0.8% | -12.0% | ||
| Q2 25 | -43.9% | -17.0% | ||
| Q1 25 | 3.9% | -15.1% | ||
| Q4 24 | -221.2% | -20.0% | ||
| Q3 24 | 2.5% | -21.0% | ||
| Q2 24 | 1.0% | -13.9% | ||
| Q1 24 | -0.5% | -8.8% |
| Q4 25 | $-0.02 | $-0.13 | ||
| Q3 25 | $-0.03 | $-0.14 | ||
| Q2 25 | $-1.66 | $-0.19 | ||
| Q1 25 | $0.14 | $-0.16 | ||
| Q4 24 | $-8.64 | $-0.21 | ||
| Q3 24 | $0.09 | $-0.21 | ||
| Q2 24 | $0.04 | $-0.13 | ||
| Q1 24 | $-0.02 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.8M | $704.4M |
| Total DebtLower is stronger | $90.3M | — |
| Stockholders' EquityBook value | $778.2M | $887.4M |
| Total Assets | $1.1B | $1.3B |
| Debt / EquityLower = less leverage | 0.12× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $89.8M | $704.4M | ||
| Q3 25 | $70.5M | $651.1M | ||
| Q2 25 | $90.3M | $611.7M | ||
| Q1 25 | $97.0M | $563.5M | ||
| Q4 24 | $107.7M | $522.0M | ||
| Q3 24 | $89.0M | $467.8M | ||
| Q2 24 | $92.2M | $591.3M | ||
| Q1 24 | $75.8M | $579.6M |
| Q4 25 | $90.3M | — | ||
| Q3 25 | $93.4M | — | ||
| Q2 25 | $95.7M | — | ||
| Q1 25 | $98.0M | — | ||
| Q4 24 | $125.3M | — | ||
| Q3 24 | $152.6M | — | ||
| Q2 24 | $164.9M | — | ||
| Q1 24 | $167.2M | — |
| Q4 25 | $778.2M | $887.4M | ||
| Q3 25 | $778.0M | $859.4M | ||
| Q2 25 | $776.3M | $826.5M | ||
| Q1 25 | $839.4M | $800.0M | ||
| Q4 24 | $828.5M | $773.5M | ||
| Q3 24 | $1.2B | $756.2M | ||
| Q2 24 | $1.2B | $721.4M | ||
| Q1 24 | $1.2B | $707.8M |
| Q4 25 | $1.1B | $1.3B | ||
| Q3 25 | $1.1B | $1.3B | ||
| Q2 25 | $1.0B | $1.2B | ||
| Q1 25 | $1.1B | $1.2B | ||
| Q4 24 | $1.2B | $1.1B | ||
| Q3 24 | $1.7B | $1.1B | ||
| Q2 24 | $1.7B | $1.0B | ||
| Q1 24 | $1.7B | $997.1M |
| Q4 25 | 0.12× | — | ||
| Q3 25 | 0.12× | — | ||
| Q2 25 | 0.12× | — | ||
| Q1 25 | 0.12× | — | ||
| Q4 24 | 0.15× | — | ||
| Q3 24 | 0.12× | — | ||
| Q2 24 | 0.13× | — | ||
| Q1 24 | 0.14× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.2M | $50.7M |
| Free Cash FlowOCF − Capex | $21.3M | $49.9M |
| FCF MarginFCF / Revenue | 11.8% | 34.3% |
| Capex IntensityCapex / Revenue | 3.8% | 0.6% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $43.1M | $142.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.2M | $50.7M | ||
| Q3 25 | $14.0M | $30.2M | ||
| Q2 25 | $6.8M | $36.1M | ||
| Q1 25 | $25.7M | $28.8M | ||
| Q4 24 | $57.9M | $49.1M | ||
| Q3 24 | $23.0M | $27.6M | ||
| Q2 24 | $27.8M | $16.7M | ||
| Q1 24 | $-8.0M | $17.5M |
| Q4 25 | $21.3M | $49.9M | ||
| Q3 25 | $7.0M | $28.8M | ||
| Q2 25 | $-4.2M | $35.5M | ||
| Q1 25 | $19.0M | $28.1M | ||
| Q4 24 | $53.1M | $48.5M | ||
| Q3 24 | $20.0M | $26.7M | ||
| Q2 24 | $21.9M | $16.0M | ||
| Q1 24 | $-12.1M | $16.6M |
| Q4 25 | 11.8% | 34.3% | ||
| Q3 25 | 3.9% | 21.0% | ||
| Q2 25 | -2.4% | 27.9% | ||
| Q1 25 | 11.3% | 23.0% | ||
| Q4 24 | 29.6% | 41.8% | ||
| Q3 24 | 11.7% | 24.5% | ||
| Q2 24 | 12.8% | 15.5% | ||
| Q1 24 | -7.3% | 16.6% |
| Q4 25 | 3.8% | 0.6% | ||
| Q3 25 | 3.9% | 1.0% | ||
| Q2 25 | 6.3% | 0.5% | ||
| Q1 25 | 4.0% | 0.5% | ||
| Q4 24 | 2.7% | 0.5% | ||
| Q3 24 | 1.8% | 0.9% | ||
| Q2 24 | 3.4% | 0.7% | ||
| Q1 24 | 2.5% | 0.8% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 3.89× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.35× | — | ||
| Q2 24 | 15.44× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVNS
| Enteral Feeding | $83.0M | 46% |
| Radiofrequency Ablation | $36.9M | 20% |
| Neonate Solutions | $32.1M | 18% |
| Surgical Pain And Recovery | $24.7M | 14% |
| Corporate Other | $4.2M | 2% |
FROG
Segment breakdown not available.
